Skip to main content

Table 2 Description of G-CSF use and occurrence of neutropenic events in study sample (breast cancer and NHL patients)

From: The use of chemotherapy regimens carrying a moderate or high risk of febrile neutropenia and the corresponding management of febrile neutropenia: an expert survey in breast cancer and non-Hodgkin's lymphoma

  Breast cancer regimens NHL regimens
Outcome FEC
(n = 73)
FEC-T
(n = 60)
All
(n = 161)
Dose-dense
(n = 11)
All
(n = 39)
Patients with G-CSF use n (%) n (%) n (%) n (%) n (%)
Primary prophylaxis (PP) 0 1 (2) 1 (<1) 3 (27) 10 (26)
Secondary prophylaxis (SP) 36 (49) 23 (38) 67 (42) 7 (64) 16 (41)
due to FN (SP-FN) 23 (32) 17 (28) 47 (29) 6 (55) 13 (33)
Total patients developing FN a 23 (32) 19 (32) 50 (31) 7 (64) 16 (41)
Cycle # to start SP b Mean cycle # Mean cycle # Mean cycle # Mean cycle # Mean cycle #
After FN 3.2 3.4 3.4 2.5 2.7
After PSN 2.1 2 2.1 2.0 2.0
Total number of cycles observed 424 402 969 49 208
Cycles protected by G-CSF (% observed cycles) 145 (34) 103 (26) 287 (30) 36 (73) 114 (55)
  Neutropenic events by presence of PP/SP
N patients with at least one unprotected cycle 73 59 160 8 29
N (%) patients with event in unprotected cycles (first event only) 36 (49) 25 (42) 70 (44) 7 (88) 17 (58)
Of which FN 23 (32) 19 (32) 50 (31) 6 (75) 14 (48)
N patients with at least one protected cycle 36 24 68 10 26
N (%) patients with event in protected cycles 2 (6) 0 3 (4) 1 (10) 8 (31)
after PP NA 0 0 1 (10) 2 (8)
after SP 2 (6) 0 3 (4) 0 6 (23)
  Impact of FN on chemotherapy delivery (N patients and % among those who developed FN)
Dose adjustment 4 (17) 4 (21) 12 (24) 0 0
Dose delay 5 (22) 3 (16) 12 (24) 3 (43) 6 (38)
At least 1 cycle dropped 2 (9) 5 (26) 8 (16) 0 0
Switch chemotherapy protocol 3 (13) 2 (11) 6 (12) 0 0
Any type 8 (35) 8 (42) 20 (40) 3 (43) 6 (38)
  1. This table summarizes, for different subgroups of chemotherapy regimens, the number of patients receiving each type of G-CSF prophylaxis, and the number of patients experiencing severe neutropenic events, depending on the presence of protected/unprotected cycles. The consequences of FN on the chemotherapy delivery are also presented.
  2. aPatients who developed FN at the last cycle did not receive SP-FN
  3. bIf FN in cycle n, SP starts in cycle (n + 1)
  4. NA: not applicable